Leire Balaguer Lluna
Investigador pre-doc
Research group
BSc Biochemistry and Biomedical science (2016) Universidad de Valencia. Master in Genetics (2017) Universidad Autonoma de Barcelona.
Professional network profiles
Last Publications
- Balaguer-Lluna L, Gene-Olaciregui N, Aschero MR, Resa-Parés C, Paco-Mercader S, Cuadrado-Vilanova M, Burgeño-Sandoval V, Baulenas-Farrés M, Monterrubio C, Manzanares-Quintela A, Rodriguez E, Lavarino C, Mora J and Carcaboso AM Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas JOURNAL OF NEURO-ONCOLOGY . : .
- Zugbi S, Aschero R, Ganiewich D, Cancela MB, Winter U, Ottaviani D, Sampor C, Dinardi M, Torbidoni AV, Mena M, Balaguer-Lluna L, Lamas G, Sgroi M, Lagomarsino E, Lubieniecki F, Fandiño A, Radvanyi F, Abramson DH, Podhajcer O, Llera AS, Cafferata EG, Chantada G, Carcaboso AM and Schaiquevich P Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE . 64(15): 27-27.
- Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408.
Projects
- Project name:
- Contratos predoctorales de formación en investigación en salud_Beneficiari: Leire Balaguer
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- FI22/00160
- Starting - finishing date:
- 2023 - 2026
- Project name:
- Immune microenvironment of retinoblastoma
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00216
- Starting - finishing date:
- 2022 - 2026
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.